India’s Sun Pharma Begins Open Offer For Taro at $7.75
This article was originally published in PharmAsia News
Executive Summary
NEW DELHI - India's Sun Pharma said its Alkaloida Chemical unit started a tender offer for all shares of Israel's Taro Pharmaceutical as part of a disputed $460 million merger agreement reached a year ago, but unilaterally cancelled by Taro in late May